Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP3A4*22 genotype-guided dose reduction of CYP3A4-metabolized tyrosine kinase inhibitors in adults with cancer
NL-OMON25948Recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2019
- Countries
- 1
01
Overview
Open-label trial in cancer (2 arms), sponsored by Erasmus MC. Primary endpoint: Trough exposure comparison. Started Feb 2019; status: recruiting.
02
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON25948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25948.